The ideal way to design clinical trials and establishment of evidence for human cellular and tissue‐based products in Japan-Reference-Cited by-同舟云学术

The ideal way to design clinical trials and establishment of evidence for human cellular and tissue‐based products in Japan

Published:2019-04-24 Issue: Volume: Page:
ISSN:1932-6254
Container-title:Journal of Tissue Engineering and Regenerative Medicine
language:en
Short-container-title:J Tissue Eng Regen Med

Author:

Sawa Yoshiki¹^ORCID

Affiliation:

1. Division of Cardiovascular Surgery, Department of SurgeryOsaka University Graduate School of Medicine Suita Japan

Publisher

Wiley

Subject

Biomedical Engineering,Biomaterials,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/term.2852

Reference14 articles.

1. Recent policies that support clinical application of induced pluripotent stem cell‐based regenerative therapies;Azuma K.;Regenerative Therapy.,2016

2. European Medicines Agency (EMA). (20 October2017).European Commission‐DG Health and Food Safety and European Medicines Agency Action Plan on ATMPs. Available at:http://www.ema.europa.eu/docs/en_GB/document_library/Other/2017/10/WC500237029.pdf(accessed 25 December 2018)

3. Government of Japan. (10 May2013a).Act for the Promotion of Regenerative Medicine [in Japanese] Act No. 13 of May 10.2013. Available at:https://www.mhlw.go.jp/file/06‐Seisakujouhou‐10800000‐Iseikyoku/0000150835.pdf(accessed 25 December 2018)

4. Government of Japan. (27 November 2013b).Pharmaceuticals and Medical Devices Act [in Japanese] Act No. 103 of Nov. 2013”. Available at:https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/dl/140825_0‐1.pdf(accessed 25 December 2018)

5. Skeletal myoblast transplantation in ischemic heart failure: long‐term follow‐up of the first phase I cohort of patients;Hagège A. A.;Circulation,2006